

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**天津泰達生物醫學工程股份有限公司**  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 8189)**

### **UNUSUAL PRICE MOVEMENT**

This announcement is made at the request of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") in accordance with Rule 17.11 of the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange ("GEM Listing Rules").

The board (the "Board") of directors (the "Directors") of Tianjin TEDA Biomedical Engineering Company Limited (the "Company") has noted the unusual price movement of the shares of the Company ("Shares") today and wishes to state that the Board is not aware of any reasons for such movement in the price of the Shares.

The Board wishes to announce that the Company is considering a possible placing. However, no formal agreement nor terms had been finalised nor signed.

Save as disclosed above, the Board also confirms that there are no negotiations or agreements relating to intended acquisitions or realisations which are discloseable under Chapters 19 and 20 of the GEM Listing Rules, neither is the Board aware of any matter discloseable under the general obligation imposed by Rule 17.10 of the GEM Listing Rules, which is or may be of a price-sensitive nature.

Made by the order of the Board, the Directors of which collectively and individually accept responsibility for the accuracy of this announcement.

By Order of the Board  
**Wang Shuxin**  
*Chairman*

Tianjin, the PRC  
8 December 2011

*As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Wang Shuxin, Mr. Hao Zhihui and Mr. Zhang Chunsheng, three non-executive Directors, namely, Mr. Feng Enqing, Mr. Xie Guangbei and Mr. Ou Linfeng and three independent non-executive Directors, namely, Mr. Guan Tong, Mr. Wu Chen and Mr. Cao Kai.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*